228 related articles for article (PubMed ID: 8187080)
21. A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
Hashimoto S; Danks MK; Chatterjee S; Beck WT; Berger NA
Oncol Res; 1995; 7(1):21-9. PubMed ID: 7549041
[TBL] [Abstract][Full Text] [Related]
22. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
[TBL] [Abstract][Full Text] [Related]
23. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
24. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Kingma PS; Burden DA; Osheroff N
Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
[TBL] [Abstract][Full Text] [Related]
25. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
Nitiss JL; Zhou J; Rose A; Hsiung Y; Gale KC; Osheroff N
Biochemistry; 1998 Mar; 37(9):3078-85. PubMed ID: 9485461
[TBL] [Abstract][Full Text] [Related]
26. Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Glisson BS; Sullivan DM; Gupta R; Ross WE
NCI Monogr; 1987; (4):89-93. PubMed ID: 2819738
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
28. A topoisomerase II poison screen of ethnomedicinal Thai plants using a yeast cell-based assay.
Sangmalee S; Laorpaksa A; Sukrong S
J Ethnopharmacol; 2012 Jul; 142(2):432-7. PubMed ID: 22735665
[TBL] [Abstract][Full Text] [Related]
29. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
[TBL] [Abstract][Full Text] [Related]
30. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Vassetzky YS; Alghisi GC; Gasser SM
Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
[TBL] [Abstract][Full Text] [Related]
31. [Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].
Gushchin AE; Ladygina VG; Govorun VM
Mol Gen Mikrobiol Virusol; 1999; (4):19-24. PubMed ID: 10621934
[TBL] [Abstract][Full Text] [Related]
32. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
33. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
34. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
Keller BA; Patel S; Fisher LM
Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
[TBL] [Abstract][Full Text] [Related]
35. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
36. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.
Dereuddre S; Delaporte C; Jacquemin-Sablon A
Cancer Res; 1997 Oct; 57(19):4301-8. PubMed ID: 9331091
[TBL] [Abstract][Full Text] [Related]
37. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
38. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
Patel S; Keller BA; Fisher LM
Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
[TBL] [Abstract][Full Text] [Related]
39. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
40. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Okada Y; Tosaka A; Nimura Y; Kikuchi A; Yoshida S; Suzuki M
Gene; 2001 Jul; 272(1-2):141-8. PubMed ID: 11470519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
